183 related articles for article (PubMed ID: 35785180)
1. Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.
Yang C; Cui Y; Ren X; Li M; Yu K; Shen S; Jiang H; Li M; Zhang X; Zhao X; Zhu Q; Lin S
Front Oncol; 2022; 12():901797. PubMed ID: 35785180
[TBL] [Abstract][Full Text] [Related]
2. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
[No Abstract] [Full Text] [Related]
3. Bruton's tyrosine kinase inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A meta-analysis and systematic review.
Guo HP; Dang XL; Kang L; Liu C; Liu XW
World Neurosurg; 2024 Apr; ():. PubMed ID: 38641241
[TBL] [Abstract][Full Text] [Related]
4. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
Wu JJ; Wang WH; Dong M; Ma SS; Zhang XD; Zhu LN; Niu ST; Ding MJ; Zhang JM; Zhang L; Li X; Li L; Sun ZC; Wang XH; Fu XR; Li ZM; Chang Y; Nan FF; Yan JQ; Yu H; Wu XL; Zhou ZY; Zhang MZ
Invest New Drugs; 2022 Jun; 40(3):650-659. PubMed ID: 35137332
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of the Short-Term Efficacy and Safety of Orelabrutinib Combined with High-Dose Methotrexate in the First-line Treatment of Elderly Patients with High Risk Primary Central Nervous System Lymphoma].
Xie Y; Qu S; Liao LS; Zheng ZH; Lin Y; Chen WM; Chen BY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1714-1719. PubMed ID: 38071050
[TBL] [Abstract][Full Text] [Related]
6. Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis.
Qiao L; Liu Q; Huang C
Medicine (Baltimore); 2023 Jul; 102(27):e33880. PubMed ID: 37417642
[TBL] [Abstract][Full Text] [Related]
7. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
Schaff L; Nayak L; Grommes C
Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38597202
[TBL] [Abstract][Full Text] [Related]
8. Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
Zhou Y; Wang X; Lin X; Wang J; Yan X; Wen Y
AIDS Res Ther; 2023 Aug; 20(1):63. PubMed ID: 37644480
[TBL] [Abstract][Full Text] [Related]
9. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Deng L; Li Z; Zhang H; Huang H; Hu J; Liu L; Liu T; Jin J; Zhu Z; Li W; Huang Z; Huang W; Zhou K; Yang H; Zhang M; Ding K; Zhou H; Hu Y; Shuang Y; Cao J; Gao S; Li D; Sun Z; Zhang Q; Yi S; Ji C; Zhang L; Hou C; Du Y; Wang W; Zhao R; Song Y; Zhu J
Am J Hematol; 2023 Nov; 98(11):1742-1750. PubMed ID: 37647123
[TBL] [Abstract][Full Text] [Related]
10. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
Xu W; Zhou K; Wang T; Yang S; Liu L; Hu Y; Zhang W; Ding K; Zhou J; Gao S; Xu B; Zhu Z; Liu T; Zhang H; Hu J; Ji C; Wang S; Xia Z; Wang X; Li Y; Song Y; Ma S; Tang X; Zhang B; Li J
Am J Hematol; 2023 Apr; 98(4):571-579. PubMed ID: 36683422
[TBL] [Abstract][Full Text] [Related]
11. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.
Yu H; Wang X; Li J; Ye Y; Wang D; Fang W; Mi L; Ding N; Wang X; Song Y; Zhu J
Mol Ther Oncolytics; 2021 Jun; 21():158-170. PubMed ID: 33981831
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
[TBL] [Abstract][Full Text] [Related]
14. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
[TBL] [Abstract][Full Text] [Related]
15. Targets and treatments in primary CNS lymphoma.
von Roemeling C; Ferreri AJM; Soussain C; Tun HW; Grommes C
Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38659230
[TBL] [Abstract][Full Text] [Related]
16. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma.
Yang Y; Li Q; Ma J; Kang H; Lin Z; Wang Y; Ma Y; Chen B
Front Oncol; 2023; 13():1098785. PubMed ID: 37182159
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.
Cao XX; Jin J; Fu CC; Yi SH; Zhao WL; Sun ZM; Yang W; Li DJ; Cui GH; Hu JD; Liu T; Song YP; Xu B; Zhu ZM; Xu W; Zhang MZ; Tian YM; Zhang B; Zhao RB; Zhou DB
EClinicalMedicine; 2022 Oct; 52():101682. PubMed ID: 36313145
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study.
Ma J; Lin Z; Ding T; Li Q; Zhang M; Kang H; Johnston PB; Ma Y; Chen B
Front Oncol; 2022; 12():938421. PubMed ID: 35898888
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
